Agaricus mushroom Supplements: Extract Research, Mixtures and Liver Safety

How are Agaricus mushrooms used in supplements?

Agaricus supplements include mushroom powders, concentrated extracts and liquid mixtures sold for immune, bowel or metabolic effects. Medicinal products commonly use Agaricus blazei Murrill and related names for this cultivated mushroom. This article compares those preparations with studies of ordinary button mushrooms, Agaricus bisporus, including cooked food and powder. The species and preparation determine which study can inform a product claim.

How do historical uses compare with modern products?

Memorial Sloan Kettering^[1] describes medicinal Agaricus blazei as an edible mushroom native to Brazil and cultivated in Japan for medicinal use. Names include Cogumelo do Sol, or sun mushroom, and Himematsutake. Its account lists uses for diabetes, high cholesterol, hepatitis and cancer, alongside forms ranging from food and tea to concentrated extracts. These are documented uses, with much less clinical evidence than the range of claims might suggest.

The naming matters. A taxonomic investigation^[2] connected the cultivated Brazilian medicinal mushroom sold under several names with Agaricus subrufescens. That does not make it the same preparation as the ordinary button mushroom, A. bisporus, or the field mushroom, A. campestris. Older references to “Agaricus” also need a species and preparation match before they can establish the history of a modern supplement.

The history is not described consistently. A 2004 account by Brazilian researchers^[3] described Japanese interest as growing from late-twentieth-century experimental research and characterized medicinal-mushroom interest in Brazil as recent. Its authors disputed an established Brazilian mushroom-medicine tradition. That is a historical assessment, rather than proof that no community ever used the mushroom, but it argues against presenting every modern claim as an ancient Brazilian practice.

The field mushroom has a separate record. Korea’s Traditional Knowledge Portal^[4] identifies A. campestris fruiting bodies under the name Mago and lists uses for digestive complaints and insufficient milk production. This documents a traditional-use account; the extract trials below do not test that field-mushroom preparation for those purposes.

Older European names need similar care. In Francis Adams’s translation of Paulus Aegineta^[5], the entry for “agaric” describes a growth from a tree trunk and discusses it in terms of humours and internal obstructions. That description cannot establish that a modern Agaricus blazei or field-mushroom supplement was the remedy used in Byzantine medicine.

Modern studies below test named extracts, mixed liquids, mushroom powder or cooked food. Their results answer narrower questions than whether mushrooms have a long history of use.

What are the safety concerns?

Why do people take medicinal Agaricus?

The bowel studies below tested a three-mushroom mixture; the cancer studies tested named extracts and did not establish a survival benefit. For someone with inflammatory bowel disease or cancer, the treating team can assess whether liver disease, allergy or treatment interactions make a proposed product unsuitable. Bring its label, daily amount and your medicine list to that discussion.

What should you check on the label?

Compare the species, preparation and amount in the full daily serving with the study being cited. “Agaricus” alone does not identify the tested extract, and a blend’s total weight does not tell you how much of each mushroom it contains. A product citing a mixture trial should name the other mushrooms and should not imply that Agaricus alone produced the result.

What do the human studies show?

Bowel symptoms: mixed results, without a clear inflammation benefit

An AndoSan study in Crohn's disease^[7] used 60 mL daily of a mixture: 82.4% Agaricus, 14.7% lion's mane and 2.9% maitake. The results section reports 76 people randomized and 50 analyzed over twenty-one days. Symptoms improved within the mixture group, but the overall comparison with placebo was not statistically clear. Fatigue, overall quality of life and the stool inflammation marker calprotectin did not show a convincing advantage. One symptom item, stool frequency, favored the mixture, but the overall symptom result remained inconclusive. The study did not establish healing of the bowel lining.

The authors disclosed patents and financial interests related to the product, including a shareholder relationship with its commercializer. Patients did not know their assigned drink, but researchers did know; that can influence interactions and assessment. Those design limits and commercial interests matter when judging this small study.

A separate ulcerative-colitis trial^[8] had a more favorable result with the same daily mixture for 21 days. It randomized 62 people and analyzed 50. Symptom and fatigue scores improved more than with placebo, as did some quality-of-life measures. The stool inflammation marker calprotectin did not clearly improve. Researchers knew the assignments, some participants were excluded from analysis, and the symptom scale differed from the planned instrument. The product supplier and author commercial interests also matter here.

A related cytokine study^[9] described only limited effects on inflammatory blood markers. An earlier uncontrolled study^[10] used 60 mL daily for twelve days and reported several marker changes; the later controlled studies did not confirm a calprotectin advantage. MSK^[1] also describes both favorable preliminary studies and negative findings. The research is not one consistent clinical success story.

Cancer care: immune measurements, symptoms and survival

A 2004 comparison during chemotherapy^[11] involved 100 patients with cervical, ovarian or endometrial cancer. It compared the named Agaricus blazei Murill Kyowa extract with a control group: 39 received the extract and 61 were controls. Natural-killer-cell activity was higher with the extract, while other tested immune activities and cell counts did not clearly differ. The abstract also reports improvements in complaints such as appetite and weakness, without giving their size. It does not establish how much benefit patients experienced or a survival advantage.

A different randomized trial in multiple myeloma^[12] tested AndoSan during high-dose chemotherapy and stem-cell transplant care. Forty people were randomized and 33 completed the study-product period. Some immune markers changed, but treatment response, time to new treatment and overall survival did not clearly improve. The company supplied the product and supported laboratory work; an author was a company cofounder and shareholder. These results distinguish an immune measurement from successful cancer treatment.

A small diabetes trial found lower insulin resistance

A 12-week trial in type 2 diabetes^[13] added 1,500 mg of Agaricus extract daily or cellulose placebo to metformin and gliclazide. It enrolled 72 adults; the reported end-of-study results came from 29 extract users and 31 controls. HOMA-IR, an estimate of insulin resistance, averaged 3.6 with the extract versus 6.6 with placebo. Lower values indicate less insulin resistance; this result favored the extract on that measure.

That is a small, short-term adjunct study with fewer people in the reported results than were enrolled. It supports further research on this preparation, while leaving long-term diabetes complications and medication replacement unanswered.

Button mushrooms: saliva antibodies rose, vaccine benefit remained unclear

Button-mushroom studies involve A. bisporus, not the medicinal extract used in the diabetes trial. In a 24-person food study^[14], 12 healthy volunteers ate 100 g of blanched white button mushrooms daily for one week, and 12 continued their usual diet without them. Salivary IgA, an antibody measured in saliva, rose during the first two weeks and returned to baseline by the third. The study measured an immune marker rather than respiratory infections.

The Mushboost results published in 2026^[15] provide a different test. Adults aged 60 or older took 5 g daily of a specific button-mushroom powder or placebo for about four weeks before and four weeks after influenza vaccination. The paper reports 42 people in the mushroom group and 43 in the control group. It found no statistically clear improvement in the measured vaccine-antibody responses, quality of life or influenza-like illness. A numerical rise in one antibody measure was not statistically conclusive. Thus, the favorable saliva finding does not establish that a mushroom capsule improves vaccine protection.

What about aromatase and other proposed mechanisms?

White button mushroom extracts have inhibited aromatase^[16], an enzyme involved in estrogen production, in laboratory experiments. Further work^[17] investigated fatty-acid constituents and breast-cancer cells and mice. This explains interest in the mushroom, but a laboratory enzyme effect is not a demonstrated breast-cancer prevention benefit from food or supplements.

A 2011 dose-finding study^[18] tested freeze-dried button-mushroom tablets in 24 postmenopausal breast-cancer survivors who were recurrence-free and off treatment. Six women per group took 5, 8, 10 or 13 g daily for 12 weeks. None met the planned target of reducing free estradiol by at least half. Higher doses changed an experimental aromatase measurement, but estrogen levels did not significantly fall from baseline. This small meeting report did not demonstrate cancer prevention.

Mouse-cell experiments with isolated mushroom compounds^[19] also help explain interest in immune effects. Extract composition and human outcomes still have to be tested: even a trial in 57 older women^[20] using 900 mg of dry extract daily for 60 days found no detectable change in the inflammatory markers it measured.

Bottom line

Medicinal Agaricus has limited, preparation-specific human evidence. Mixed-extract findings cannot establish an Agaricus-only benefit. The button-mushroom food and powder studies answer separate questions and have mixed findings. Serious liver reports and individual treatment compatibility deserve review before concentrated use.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly